Association of lipid-lowering drugs, anti-diabetic drugs, non-steroidal anti-inflammatory drugs, and levodopa with age-related macular degeneration in Europeans: A meta-analysis of the European Eye Epidemiology (E3) - consortium - Université de Bourgogne Accéder directement au contenu
Communication Dans Un Congrès Année : 2022

Association of lipid-lowering drugs, anti-diabetic drugs, non-steroidal anti-inflammatory drugs, and levodopa with age-related macular degeneration in Europeans: A meta-analysis of the European Eye Epidemiology (E3) - consortium

Anthony P. Khawaja
Fotis Topouzis
  • Fonction : Auteur
  • PersonId : 869261
Cecile Delcourt
Robert Finger

Résumé

Purpose : Changes in lipid metabolism, chronic inflammation and increased oxidative stress have been discussed as patho-etiogenetic drivers in age-related macular degeneration (AMD). Systemic medication, such as lipid-lowering drugs (LLD) and anti-diabetic drugs, affect these pathways and may therefore also play a role in AMD pathogenesis. We aimed to investigate associations of commonly used systemic drugs with AMD prevalence in the European population. Methods : We included 38,694 adults from 14 population-based studies from the European Eye Epidemiology (E3) consortium. We performed multivariable logistic regression modelling to examine medication use association with prevalence of AMD as well as late AMD. Analyses were carried out separately by study and results pooled using random effects meta-analysis. We conducted these analyses separately for LLD, anti-diabetic drugs, non-steroidal anti-inflammatory drugs (NSAID), and L-Dopa. Results : Between studies, mean age ranged from 61.5 ± 7.1 to 82.6 ± 3.8 years and prevalence ranged from 12.1% to 64.5% and from 0.5% to 35.5% for any and any late AMD, respectively. In the meta-analysis of our multivariable models, LLD and anti-diabetic drugs were associated with lower AMD prevalence (OR 0.85, 95% confidence interval (CI)=0.79 - 0.91 and OR 0.78, 95% CI=0.66 - 0.91). We found no association with late AMD or with any other medication. Conclusions : Our study shows an association of LLD and anti-diabetic drug use with lower AMD prevalence across multiple European cohorts. Our findings support the importance of metabolic processes in the complex etiology of AMD.
Fichier non déposé

Dates et versions

hal-03827414 , version 1 (24-10-2022)

Identifiants

  • HAL Id : hal-03827414 , version 1
  • WOS : 000844401301045

Citer

Matthias M. Mauschitz, Alexander Karl-Georg Schuster, Anthony P. Khawaja, Mukharram Bikbov, Ruth E. Hogg, et al.. Association of lipid-lowering drugs, anti-diabetic drugs, non-steroidal anti-inflammatory drugs, and levodopa with age-related macular degeneration in Europeans: A meta-analysis of the European Eye Epidemiology (E3) - consortium. Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO), May 2022, Denver, Colorado, United States. 1 p. ⟨hal-03827414⟩
27 Consultations
0 Téléchargements

Partager

Gmail Facebook X LinkedIn More